Compare YHC & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | SHPH |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.1M |
| IPO Year | 2023 | 2022 |
| Metric | YHC | SHPH |
|---|---|---|
| Price | $1.91 | $4.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 93.1K | 28.6K |
| Earning Date | 12-01-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,120,622.00 | N/A |
| Revenue This Year | $1,254.00 | N/A |
| Revenue Next Year | $21.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.42 | N/A |
| 52 Week Low | $1.21 | $0.38 |
| 52 Week High | $4,480.00 | $8.88 |
| Indicator | YHC | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 32.83 |
| Support Level | $1.39 | $2.83 |
| Resistance Level | $2.09 | $4.49 |
| Average True Range (ATR) | 0.28 | 0.44 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 50.00 | 9.69 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.